Table 2.
LLOQ determination
| Donor/peptide combination | Donor ID | Peptide stimulus | Mean SFU/wella | No. runs with CV ≤30% |
|---|---|---|---|---|
| 1 | Donor 4 | CMVpp65b | 221.5 | 6 |
| 2 | Donor 1 | FVIIIc pool 2 | 82.2 | 6 |
| 3 | Donor 1 | FVIII pool 3 | 75.1 | 6 |
| 4 | Donor 4 | FVIII pool 4 | 44.4 | 6 |
| 5 | Donor 5 | FVIII pool 4 | 41.8 | 0 |
| 6 | Donor 4 | FVIII pool 2 | 39.3 | 3 |
| 7 | Donor 5 | FVIII pool 2 | 37.7 | 0 |
| 8 | Donor 5 | FVIII pool 1 | 33.2 | 1 |
| 9 | Donor 2 | FVIII pool 2 | <LOD | N/A |
| 10 | Donor 2 | CMVpp65 | <OD | N/A |
| 11 | Donor 3 | FVIII pool 2 | <LOD | N/A |
| 12 | Donor 3 | CMVpp65 | <LOD | N/A |
| 13 | Donor 6 | FVIII pool 2 | <LOD | N/A |
| 14 | Donor 6 | CMVpp65 | <LOD | N/A |
Bold indicates values selected as LLOQ.
Cell-plating density was 200,000 PBMCs/well and viability was ≥70% for all donor samples across all runs.
CMVpp65, 65 kDa phosphoprotein of cytomegalovirus.
FVIII, transgene product.